CRA International (CRAI) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.8 per share. This compares to earnings of $1.77 per share a year ago.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is how CRA International (CRAI) and Adeia (ADEA) have performed compared to their sector so far this year.
CRAI stock has surged 19.3% on strong Q2 results, rising dividends and share buybacks, even as liquidity pressures linger.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in stocks from the Consulting Services sector have probably already heard of CRA International (CRAI) and Equifax (EFX). But which of these two companies is the best option for those looking for undervalued stocks?
CRAI posts a 9% revenue jump and raises 2025 guidance as Q2 EPS and EBITDA margin both improve year over year.
CRA International, Inc. (NASDAQ:CRAI ) Q2 2025 Earnings Conference Call July 31, 2025 10:00 AM ET Company Participants Chad Holmes - Executive VP, Chief Corporate Development Officer, Interim CFO & Treasurer Paul A. Maleh - Chairman, President & CEO Conference Call Participants Andrew Owen Nicholas - William Blair & Company L.L.C.
CRA International (CRAI) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $1.83 per share a year ago.
CRA (CRAI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CRAI boosts dividends and buybacks amid strong niche demand, but rising costs and a slipping current ratio tighten its liquidity outlook.
I am upgrading CRA International to Buy at ~$180 as improved margins and earnings growth have tipped the balance favorably from risk to reward. Strong demand in Antitrust, Energy, Intellectual Property, and Life Sciences have driven record results in recent quarters, with management reaffirming its bullish 2025 outlook. Also attractive are the 4% total shareholder yield (combining a stable dividend and generous stock buybacks) and a clean balance sheet.